1. Home
  2. KURA vs REX Comparison

KURA vs REX Comparison

Compare KURA & REX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KURA
  • REX
  • Stock Information
  • Founded
  • KURA 2014
  • REX 1980
  • Country
  • KURA United States
  • REX United States
  • Employees
  • KURA N/A
  • REX N/A
  • Industry
  • KURA Biotechnology: Biological Products (No Diagnostic Substances)
  • REX Major Chemicals
  • Sector
  • KURA Health Care
  • REX Industrials
  • Exchange
  • KURA Nasdaq
  • REX Nasdaq
  • Market Cap
  • KURA 793.2M
  • REX 800.0M
  • IPO Year
  • KURA N/A
  • REX N/A
  • Fundamental
  • Price
  • KURA $7.26
  • REX $41.78
  • Analyst Decision
  • KURA Strong Buy
  • REX Strong Buy
  • Analyst Count
  • KURA 11
  • REX 1
  • Target Price
  • KURA $27.89
  • REX $55.00
  • AVG Volume (30 Days)
  • KURA 1.7M
  • REX 200.0K
  • Earning Date
  • KURA 02-25-2025
  • REX 12-03-2024
  • Dividend Yield
  • KURA N/A
  • REX N/A
  • EPS Growth
  • KURA N/A
  • REX 37.28
  • EPS
  • KURA N/A
  • REX 3.82
  • Revenue
  • KURA N/A
  • REX $671,877,000.00
  • Revenue This Year
  • KURA N/A
  • REX N/A
  • Revenue Next Year
  • KURA $233.30
  • REX $9.87
  • P/E Ratio
  • KURA N/A
  • REX $10.94
  • Revenue Growth
  • KURA N/A
  • REX N/A
  • 52 Week Low
  • KURA $6.98
  • REX $39.02
  • 52 Week High
  • KURA $24.17
  • REX $60.79
  • Technical
  • Relative Strength Index (RSI)
  • KURA 19.21
  • REX 45.33
  • Support Level
  • KURA $7.02
  • REX $41.33
  • Resistance Level
  • KURA $7.66
  • REX $43.12
  • Average True Range (ATR)
  • KURA 0.34
  • REX 1.04
  • MACD
  • KURA 0.07
  • REX 0.03
  • Stochastic Oscillator
  • KURA 13.76
  • REX 21.10

About KURA Kura Oncology Inc.

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

About REX REX American Resources Corporation

REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.

Share on Social Networks: